Embody GLP-1 review vs PlexusDx: Embody locks semaglutide refills at $299/month (~$3,438/year) after the intro tier; PlexusDx Microdose GLP-1 Protocol is $129/mo flat ($1,548/year) and Semaglutide Injection is $179–$229/mo. Both use compounded medications; PlexusDx adds the Precision Peptide Genetic Test for genetics-informed dosing.

Hers accepts HSA/FSA via reimbursement (pay with regular card, submit receipt). PlexusDx accepts HSA/FSA card payment at checkout where your plan permits, with no membership fee — protocols from $129/mo, all 50 states.

The seven non-negotiable questions to ask before any GLP-1 telehealth consult, with green/yellow/red answer guides — pharmacy identity (503A vs 503B), compounded vs FDA-approved, total cost across month one through highest maintenance dose, escalation path, and the genetic-baseline question most cash-pay platforms skip.

MEDVi vs Hers vs PlexusDx in 2026: real annual cost math, compounded vs FDA-approved branded medication source, tirzepatide availability across all three, cancellation and refund policy differences, and where the Precision Peptide Genetic Test fits when GLP-1 response varies by GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants.

MEDVi semaglutide ranges from $149 to $299/month depending on which page you land on. We reconcile every published MEDVi rate against PlexusDx Semaglutide Injection ($179-$229/mo) and Semaglutide Oral (from $209/mo) on a 12-month total-cost basis — with the genetic baseline MEDVi doesn’t offer.

Pennsylvania Medicaid cut GLP-1 coverage for adult weight loss on January 1, 2026. This guide walks the legal cash-pay telehealth options that ship to PA, the compounded vs FDA-approved branded distinction, real annualized costs, and where PlexusDx Microdose GLP-1 ($129/mo), Semaglutide Injection ($179–$229/mo), and Tirzepatide Injection ($229–$309/mo) sit relative to Eden, Ro, TrimRx, Willow, and MEDVi — with the optional Precision Peptide Genetic Test anchoring dose decisions to your DNA before week one.